Table 1

Central macular thickness (CMT) and best-corrected visual acuity (BCVA) before and at 1, 2 and 3 months after monthly injection of intravitreal ziv-aflibercept

Baseline1 month2 months3 months
Combined treatment-naïve and non-naïve cases
 Number of eyes17171715*
 CMT, mean±SD517.5±128.6355.4±82.3 (p=0.001)345.5±116.9 (p<0.001)322.2±101.5 (p=0.001)
 BCVA, log MAR±SD (range)0.70±0.38 (0.1–1.3)0.49±0.30 (0.0–1.0) (p=0.003)0.43±0.28 (0.0–0.9) (p=0.002)0.42±0.29 (0.0–0.85) (p=0.002)
Treatment-naïve cases
 Number of eyes5555
 CMT, mean±SD519.2±57.5343.2±100.5334.0±88.9341.0±102.4
 BCVA, log MAR±SD (range)1.02±0.18 (0.8–1.3)0.66±0.21 (0.3–0.85)0.54±0.32 (0.15–0.9)0.53±0.19 (0.4–0.85)
Treatment non-naïve cases
 Number of eyes12121210
 CMT, mean±SD516.8±151.2360.4±78.0350.3±130.1310.7±104.6
 BCVA, log MAR±SD (range)0.57±0.360.42±0.310.39±0.260.37±0.32
  • p Value is measured against baseline values using the Wilcoxon-signed rank test.

  • *Two patients could not come for the 3-month follow-up because they were too sick to travel long distance.